Form 4: Neurocrine Biosciences CSO Executes Stock Option Plan

Chief Scientific Officer Jude Onyia exercised options and sold 11,000 shares of Neurocrine Biosciences common stock.

Summary

• Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences, exercised 11,000 stock options at a strike price of $84.74.
• Following the exercise, the reporting person sold 11,000 shares at a weighted average price of $160.2464 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
• The reporting person retains beneficial ownership of 25,846 shares of common stock following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-established 10b5-1 trading plan, which is a routine mechanism for executive compensation realization.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating a systematic approach to equity management rather than reactive selling.

Negatives

• The transaction represents a divestment of equity by a key member of the executive leadership team.

Risks

• None identified in this filing.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales executed via 10b5-1 plans are standard corporate practice for liquidity and diversification, and generally do not signal a change in company fundamentals.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to avoid potential conflicts of interest regarding material non-public information.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and executed via a 10b5-1 plan.

Next Steps

• None mentioned.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Insider Trading, Form 4, Stock Options, Chief Scientific Officer